Category Archives: Ulcerative Colitis

Eli Lilly plans to spend $3.2 billion acquiring a Massachusetts-based biotechnology company and its experimental pill for inflammatory bowel disease. Continue reading →

At five years old, I woke up from a colonoscopy completely unaware that my life was about to change forever. A diagnosis of ulcerative colitis awaited me and would alter my future in ways I couldnt have imagined. A chronic inflammatory bowel disease that causes inflammation in the digestive tract and can include a variety of GI-related symptoms that may range from mild to severe, this diagnosis has led to 22 years of appointments, medications, and surgeries, including the removal of my large intestine Continue reading →

PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end Carlsbad,CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.(Nasdaq: PALI) (Palisade, Palisade Bio or the Company), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it presented at IBD Innovate: Product Development for Crohns & Colitis held April 9-10, 2024 in Cambridge, MA. Continue reading →

Louise Thompson has revealed she has a stoma bag to help manage her ulcerative colitis. (Getty Images) Former Made in Chelsea star Louise Thompson has revealed that she has had a stoma bag fitted Continue reading →

Ulcerative colitis is a long-term condition where the colonand rectum become inflamed. Smallulcers can develop onthe colons liningand can bleed and produce pus. The main symptoms of ulcerative colitis are recurring diarrhoea, which may contain blood, mucus or pus, stomach pain and increased stool frequency Continue reading →

Study design and patient population A single-center retrospective study design was used to investigate the follow-up of patients treated with IN between 2015 and 2020. Powdered IN (Fujian Province, China) was purchased from Uchidawakanyaku Ltd. (Tokyo, Japan) Continue reading →

Pfizers once-daily S1P receptor modulator Velsipity (etrasimod) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat moderately-to-severely active ulcerative colitis (UC). The drug has been concurrently recommended by the National Institute for Health and Care Excellence (NICE) for use in patients aged 16 years and older who have had an inadequate response, lost response or been intolerant to conventional therapy or biological treatment. Affecting approximately 300,000 people in the UK, UC is a chronic, immune-mediated condition where the colon and rectum become inflamed, causing symptoms such as frequent diarrhoea, bowel urgency, rectal bleeding, abdominal pain, fatigue, fever and anaemia. Continue reading →

Patients This was a retrospective study targeting patients with ICI-induced colitis who had undergone colonoscopy at the onset of the disease at Kyoto University Hospital, affiliated hospitals, and Kindai University Faculty of Medicine between April 2018 and April 2023. All but one patient (Case 1) was treated with only ICI treatment. ICI-induced colitis was defined as diarrhea or bloody stools following ICI administration and/or with histological evaluation [5]. Continue reading →

NICE is the organisation that decides whether treatments should be available on the NHS in England. Wales and Northern Ireland usually follow NICE decisions too. In Scotland, these decisions are made by the Scottish Medicines Consortium (SMC). Continue reading →

When I was a kid, I took lots of tripsto the bathroom. Continue reading →